Survival with chronic myeloid leukaemia after failing milestones

Therapy after failing response milestones in CML is controversial. Risks associated with comorbidities, drug toxicities or transplantation may preclude switching to another tyrosine kinase inhibitor (TKI) or other treatments. No information on long-term survival of failing patients is available. To...

Descripción completa

Detalles Bibliográficos
Autores principales: Lauseker, Michael, Hehlmann, Rüdiger, Hochhaus, Andreas, Saußele, Susanne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10624616/
https://www.ncbi.nlm.nih.gov/pubmed/37726340
http://dx.doi.org/10.1038/s41375-023-02028-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10624616/
https://www.ncbi.nlm.nih.gov/pubmed/37726340
http://dx.doi.org/10.1038/s41375-023-02028-2

Ejemplares similares